Can Q3 FY26 earnings spark further gains for Core Scientific stock?

Can Q3 FY26 earnings spark further gains for Core Scientific stock?
Core Scientific jumps 3.03% to $13.92

Core Scientific (CORZ) stock is trading at $13.92 after a daily gain of 3.03%. The price has moved higher on the day but remains below its key moving averages.

CORZ price prediction
24H 3.56%
$13.98
48H 3.19%
$13.93
7D -1.04%
$13.36
1M -13.26%
$11.71
3M -19.78%
$10.83
6M -20.3%
$10.76
12M -22.44%
$10.47
Current price: $13.5 -0.8200 5.73%
Closed 10/16
Daily range 13.51 Arrow from to Icon 14.48
Weekly range 12.37 Arrow from to Icon 15.46
Loading...

Highlights

  • Core Scientific is scheduled to report fiscal Q3 2026 results before the market opens on November 5, 2026.
  • Chief Legal and Administrative Officer Todd M. DuChene sold 10,000 shares at $15.116 each on October 12, 2026.
  • Shares of Core Scientific trade under persistent bearish technical pressure with a high probability of remaining within the $12.75 to $14.86 range.

Investor focus intensifies as earnings and insider selling converge

Core Scientific is set to release its third quarter fiscal 2026 financial results before the market opens on November 5, 2026, an announcement that, according to Businesswire, increases investor attention and may lead to heightened trading activity in anticipation of updated financial performance data. In addition, a recent Form 4 filing revealed that Todd M. DuChene, Chief Legal and Administrative Officer, sold 10,000 shares at $15.116 per share on October 12, 2026, as reported by Rallies, a move that could draw additional scrutiny to insider positioning and sentiment. These corporate disclosures contribute to the current backdrop for the shares, with investors weighing both forthcoming earnings and insider activity when calibrating near-term expectations.

Core Scientific asset chart
Core Scientific price dynamics. Source: TradingView.

Bearish momentum persists as multiple indicators signal downside risk

On the H1 timeframe, CORZ remains below the MA-20 at $14.35 and MA-50 at $15.12, while on the daily chart it is well beneath the MA-200 at $19.81. The Ichimoku Kijun level, situated at $13.91, currently serves as immediate support. Momentum indicators remain negative: MACD and ADX signal a sell bias, while the RSI is deeply oversold at 28.04. CCI is also in oversold territory. Stoch RSI is neutral, and Bull/Bear Power confirms sellers hold intraday momentum. The Awesome Oscillator further supports the prevailing downside trend, with price action showing strong volatility and a close near the session high.

Sideways bias holds unless decisive break alters short-term range

Over the upcoming sessions, CORZ is expected to oscillate within a volatility band of $12.75 to $14.86. The baseline scenario calls for sideways movement inside this corridor given the current momentum profile. Should a decisive move occur above resistance, a rebound toward the upper range could follow. Conversely, if support at $13.91 fails, further downside may open up for the stock.

Viktoras Karapetjanc, expert at Traders Union, notes that the upcoming Q3 earnings release is a clear catalyst for rising investor attention and trading activity in Core Scientific. He believes that despite some technical headwinds and the recent insider sale, sentiment around the stock is firming up as participants position ahead of the results. The analyst sees sideways consolidation as likely in the near term, with volatility providing opportunity if momentum shifts. "With earnings on the horizon and investors watching both fundamentals and sentiment, I see scope for constructive moves if key supports hold ahead of the report."

Earlier, analysts noted that Core Scientific was experiencing significant technical weakness with persistent downside risks dominating the stock’s outlook. This narrative is reinforced by fresh evidence of ongoing negative momentum, highlighting $13.91 as a critical support level to monitor for potential further downside movement in the days ahead.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.